In a systematic review and meta-analysis of randomized, placebo-controlled trials of cardiovascular outcomes in a total of 34,322 patients with T2DM, SGLT2 inhibitors showed moderate benefits on atherosclerotic major adverse cardiovascular events with established atherosclerotic cardiovascular disease [257]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.